Targeting Apelinergic System in Cardiometabolic Disease

Author(s): Rui Guo, Olivia Rogers, Sreejayan Nair*

Journal Name: Current Drug Targets

Volume 18 , Issue 15 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Background: Global burden of cardiometabolic disease warrants development of newer treatment strategies. Apelin is ubiquitously expressed endogenous peptide which is a ligand for the apelinergic (APJ) receptor. Apelin/APJ receptors regulate a variety of biological functions and have been implicated in cardiovascular and metabolic homeostasis. Consequently, the apelinergic pathway represents an attractive target to treat conditions associated with cardiometabolic syndrome.

Objective: This review highlights the important regulatory role played by apelin in energy metabolism and cardiovascular function, and potential avenues that could be harnessed for therapeutic benefit.

Conclusion: Apelin/APJ system is a druggable target to treat or prevent a variety of cardiometabolic diseases.

Keywords: Apelin, apelinergic receptor, energy metabolism, cardiovascular disease, diabetes, metabolic syndrome, polymorphism.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1785 - 1791]
Pages: 7
DOI: 10.2174/1389450117666160613105152
Price: $65

Article Metrics

PDF: 37